Browse Technologies

• 
• 
• 
• 

Despite the success of immune checkpoint inhibitors (ICI) like anti-PD-1 in treating other cancers, these therapeutics have not been demonstrated to effectively treat acute myeloid leukemia (AML). Vanderbilt researchers have identified PD-1H as a potential target for treating AML, opening the door for effective therapy using an ICI molecule.

This technology pairs a novel coil design with patient-specific stereotactic frames for precise delivery of focused ultrasound (FUS) during neuromodulation therapies. This innovative methodology enables patients to receive therapy while outside the MR environment and significantly increases the precision of noninvasive neuromodulation techniques, making treatments more accessible and effective.

An assistive device for individuals with upper extremity neuromuscular deficit has been developed by researchers at Vanderbilt. This device is specifically designed for patients having hemiplegia following stroke, incomplete spinal cord injury, multiple sclerosis, and other disabilities and conditions, who may have severe muscle weakness or inability to fully control an upper limb. In order to facilitate use of the upper limb, the patient can wear the device as a substitute for or a supplement to the patient's volitional movement.

Vanderbilt researchers have created a new multi-organs-on-chip platform that comprises Perfusion Control systems, MicroFormulators, and MicroClinical Analyzers connected via fluidic networks. The real-time combination of multiple different solutions to create customized perfusion media and the analysis of the effluents from each well are both controlled by the intelligent use of a computer-operated system of pumps and valves. This permits, for the first time, a compact, low-cost system for creating a time-dependent drug dosage profile in a tissue system inside each well.